Medicis Pharmaceutical Corp. (MRX) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts MRX Hot Sheet
Price: $68.38 +5.36%
Revenue Growth %: +21.2%
Financial Fact:
Gross profit: 160.59M
Today's EPS Names:
UVV, SII, SCKT, More
Revenue Growth %: +21.2%
Financial Fact:
Gross profit: 160.59M
Today's EPS Names:
UVV, SII, SCKT, More
Join SI Premium – FREE
Medicis Pharmaceutical Corp. (NASDAQ: MRX) reported Q3 EPS of $0.96, $0.02 better than the analyst estimate of $0.94. Revenue for the quarter came in at $484.6 million versus the consensus estimate of $475.84 million.
For earnings history and earnings-related data on Medicis Pharmaceutical Corp. (MRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citizens Reiterates Market Perform Rating on Block Inc. (XYZ)
- Novo Nordisk (NVO) Tops Q3 EPS by 117c; offers outlook
- Citi raises Keurig Dr Pepper price target to $40
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
